Purpose: Activation of the wnt pathway identifies a subgroup of hepatocellular carcinomas (HCC) with specific epidemiologic and genetic profiles. Wnt activation is predicted by mutation and/or nuclear translocation of β-catenin and by glutamine synthetase (GS) immunoreactivity. We investigated whether GS staining associates with specific pathologic features of HCC and with survival after radiofrequency thermal ablation.
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, the most frequent cause of liverrelated death, and the third cause of tumor death worldwide (1) . Despite screening strategies and new therapeutic options, HCC remains the second most lethal cancer averaging 10% survival at 5 years (2) .
HCC encompasses a heterogeneous group of subtypes with different etiologies, environmental risk factors, and transformation pathways (3) that reflect into different genomic changes and variable clinical courses (4) . Even extensively validated staging systems, aimed to allocate patients to effective treatments, do not reliably define homogenous prognostic groups (5) . This is especially critical for small, potentially curable HCCs that are increasingly diagnosed (6) . Methods able to stratify tumors based on biological principles are advocated to meet the increasing demand of differentiated treatments including new classes of biological drugs (7) .
The relevance of biological markers for HCC classification and staging remains largely unexplored (6) . Two major carcinogenetic mechanisms have been identified as follows: the first is associated with chromosomal instability, p53 and axin mutations, and AKT signaling; the second is characterized by β-catenin mutation, activation of the wnt canonical pathway, and CpG methylation (8) (9) (10) . This fundamental distinction can be replicated in transgenic and chemical models of mouse carcinogenesis (11, 12) .
β-Catenin-mutated HCCs are being delineated as a distinct clinicopathologic entity characterized by older age, nonviral etiology, and specific histologic features (10, (13) (14) (15) . However, the effect of an active β-catenin signaling pathway on outcome remains controversial (14) (15) (16) (17) (18) . β-Catenin gain-of-function mutants result in nuclear translocation of the protein (19, 20) and overexpression of downstream molecules, such as gluthamine synthetase (GS), G protein-coupled receptor 49, and glutamase transporter 1 (11, 21) , that are sensitive markers of the wnt pathway activation (13, 22) .
In the present study, a retrospective series of 207 earlystage HCCs consecutively diagnosed and uniformly treated with radiofrequency thermal ablation (RFTA) in a single tertiary teaching hospital was investigated for activation of the wnt pathway by tissue expression of β-catenin and GS. Aims of the study were to correlate β-catenin/GS status with the pathologic features of the tumors and the outcome of the patients.
Materials and Methods
Patients. Criteria for enrollment into the study were as follows: (a) a single nodule of ≤5.0 cm in maximum diameter or two or three nodules of ≤3.0 cm; (b) management by RFTA; (c) availability of pathologic tumor samples; and (d) known clinical outcome.
Over the period 2000 to 2008, 590 newly observed patients with HCC underwent RFTA, in which 454 satisfied the staging criteria. Tumor tissue was available in 247 (54.4%) of them; 207 patients, nonbiopsied or biopsied elsewhere and referred for treatment only, were excluded. Forty patients were further excluded because of inadequate pathologic samples (20) or previous history of HCC (20) . Clinical features and survival of excluded patients were not statistically different from the study base (data not shown).
The main clinical features of the 207 enrolled patients are summarized in Table 1 . There were 131 (63%) males; mean age was 70 ± 83 y; etiology of liver disease was hepatitis C in 170 cases (82.1%), hepatitis B in 5 (2.4%), alcohol in 17 (8.2%), other causes in 3 (1.5%), and it was unknown in 12 (5.8%). Patients were followed for a median time of 34 (18-46) mo.
The diagnostic process (23) included routine laboratory tests, serum α-fetoprotein (AFP) level (normal values, ≤20 ng/mL), abdominal ultrasonography, which was contrast-enhanced ultrasonography since September 2000 (24) , contrast-enhanced spiral computed tomography (CT) or magnetic resonance imaging, and esophago-gastroduodenoscopy. The diagnosis of cirrhosis was based on histology or on concordant laboratory and imaging findings. The tumor size was the largest diameter measured by imaging.
The protocol of the study was approved by the institutional review board. All participants provided written informed consent to the study procedures.
Pathologic assessment. Histology was evaluated on needle biopsy of the liver primary (195) or the recurrence (8) . In four patients, liver resections performed at recurrence following intraoperative (3) or percutaneous (1) RFTA were considered. A single nodule was present at entry in 165 patients; 2 nodules were present in 35 patients; and three nodules were present in 7 patients. Of the 256 independent nodules, 221 (86.3%) were biopsied. In 21 patients, multiple biopsies of the same nodule were available. We also examined biopsies from 14 new nodules and follow-up biopsies of 11 primary nodules.
Slides were examined according to a predefined set of variables and scored by consensus reading of two observers (BDB, EMS). The main pathologic features considered are summarized in Table 2 .
Immunohistochemical analysis of β-catenin and GS (BD Transduction Laboratories) was done according to standard procedures. Samples were considered β-catenin positive if at least 10% of nuclei were stained. GS staining was scored according to Audard et al. (13) . Positive samples showed strong cytoplasmic staining either in all (diffuse pattern) or at least 50% of the cells (mixed pattern). Normal perivenous hepatocytes were used as an internal standard (examples of immunoreactivity are shown in Supplementary Material). The sensitivity and the specificity of immunostaining was evaluated comparing paired needle and resections specimens of 68 patients from an independent series. The agreement was 87% for β-catenin (κ value, 0.0.6591; P < 0.00001) and 97% for GS staining (κ value, 0.9412; P < 0.00001; data not shown).
RFTA treatment. All patients had been considered ineligible for resection or transplant, or had spontaneously
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Tissue markers that are economic, widely applicable, reproducible, and are based on strong biological premises can be used to dissect the clinical complexity of HCC and to improve outcome prediction in addition to current staging systems. Specific signaling pathways can also represent potential targets for new drug treatments. rejected these options. Exclusion criteria included evidence of extrahepatic spread, neoplastic thrombosis in the hepatic venous systems, Child-Pugh score of ≥B8, prothrombin time ratio of ≤50% or International Normalized Ratio of ≥1.7, platelet count of ≤70 × 10 9 /l, high bleeding risk esophageal varices, Karnofsky Performance Status score of ≤90%, comorbidity associated with a life expectancy of <24 mo, tumor with difficult RFTA access, lack of patient cooperation, and refusal of treatment and/or blood transfusions.
The RFTA procedures were done as previously described (23, 25) . In most cases, percutaneous RFTA was done under local anesthesia, sometimes with conscious sedation (23) . Transarterial embolization (TAE) RFTA included transitory arterial stop-flow by occlusion of the vascular supply with a balloon catheter (25) to increase the thermal lesions. Laparoscopic (IO) RFTA under general anesthesia was reserved for nodules that were exophitic; subcapsular on surface of segments III, IV, and V; or adherent to the gallbladder wall (26) .
Abdominal ultrasonography was done 3 h after each procedure. At 24 h, ultrasonography was repeated; hemoglobin, lactate dehydrogenase, and alanine aminotransferase levels were measured; and Child-Pugh score was recalculated. Four weeks later, ultrasonography and CT or magnetic resonance imaging were done, and AFP levels were measured. Based on the 4-wk findings, treatment outcomes were classified as follows: (a) complete ablation, reflected by a nonenhancing tissue at the treatment site equal or larger in volume than the tumor and normalization of elevated AFP levels; or (b) incomplete ablation, defined as persistent enhancement at the tumor site on at least one imaging study, persistently elevated AFP levels, or both. Incomplete ablation after laparoscopic RFTA was classified as treatment failure. If percutaneous RFTA produced incomplete ablation, it was repeated within 15 d, and the results were evaluated 4 wk later. At this time, if ablation was still incomplete, the case was classified as treatment failure. Patients with treatment failures underwent percutaneous ethanol injection (27) or selective transarterial chemoembolization (28) and were followed with the rest of the cohort.
Follow-up and treatment of recurrences. Abdominal ultrasonography was done every 4 mo. CT or magnetic resonance imaging was done every 6 mo during the first year and yearly thereafter. Recurrences were defined as local when enhancing tissue reappeared <2.0 cm from the treatment margins or there was histologic evidence of viable tumor. Nonlocal recurrences included extrahepatic spread and any intrahepatic regrowth of ≥2.0 cm from the treatment margins. Nonlocal recurrence was classified as limited (1-2 nodules, ≤35 mm) or advanced. The latter category included HCC that were large (1-2 nodules, >35 mm), multifocal (≥3 nodules, any size), or massive (occupying an entire lobe or more); neoplastic thrombosis of the portal or hepatic veins; and extrahepatic metastases.
Local and limited nonlocal recurrences were managed with RFTA, provided the patient satisfied the entry criteria. Nodules that were ≤15 mm were treated with percutaneous ethanol injection or RFTA (if percutaneous ethanol injection ablation was incomplete). For patients failing to meet the enrollment, tumor debulking was done when possible. Large nonlocal recurrences were subjected to TAE-RFTA (26) . Selective transarterial chemoembolization (28, 29) was used for multifocal (local and nonlocal) and massive nonlocal recurrences. Patients with a Child-Pugh score of ≥B9 received no treatments. Extrahepatic metastases had no treatment or were treated by surgery or radiotherapy. Death was considered tumor related in patients with HCC progression at the time of death, whereas it was referred to other causes in patients who died tumor free or with tumor under control.
Statistical analysis. Means and SDs were used to summarize quantitative variables or median and interquartile range if data were not normally distributed. Count and percentage were used for qualitative variables. Incidence rates, with 95% confidence interval (CI), per 100 persons/year were calculated for overall and HCC-specific mortality. Univariate and multivariate survival analysis were assessed with the Cox method. Multivariate regression models were fitted to identify independent factors related to overall and tumor-specific mortality adjusted for competing risk to die for other causes; only variables with P < 0.2 were retained for multivariate analysis. Results were expressed as hazard ratio (HR) with 95% CI. Data analysis was done with the STATA statistical package (Stata Corp.). All tests were two sided.
Results
Classification of patients and nodules. Two hundred and seven patients with early HCC according to the Barcelona Clinic Liver Cancer staging (5, 29) were eligible for the study contributing with 235 independent nodules, 221 primaries, and 14 new nodules. Fifty-eight (24.7%) HCCs were β-catenin positive as assessed by nuclear translocation of the protein. One hundred and two of 231 (44.2%) tumors showed GS staining, 68% in a diffuse and 32% in an intermingled pattern; 4 tumors were GS indeterminate. All β-catenin-positive nodules were also immunoreactive for GS. In 32 patients, multiple biopsies of the same nodule were available; in all cases, the GS status was confirmed.
Patients were categorized according to the GS status of the nodule at entry. Ten patients had multiple nodules at diagnosis; the GS staining was concordant in seven and discordant in three patients. In the latter patients, the GS status was assigned based on the nodule showing progression during follow-up (one patient); if this was not assessable, the patient was considered GS negative. At the end, 91 patients were considered GS positive and 116 were considered negative. Biopsies of 14 new nodules were also available, whereas 7 had discrepant GS staining compared with the primary lesion.
Clinical and pathologic features of tumors. There were no clinical differences among patients according to the GS status ( Table 1 ). The mean diameter of the nodules was larger for GS-positive tumors (P = 0.012). Number of nodules, imaging features, and preoperative AFP levels were comparable between groups (Tables 1 and 2 ). The longer median follow-up time of patients with GS-positive tumors (35 versus 30 months, P = not significant) can be explained by their longer survival.
Pathologic features were evaluated in the 235 independent nodules and were significantly different between groups as summarized in Table 2 . GS-positive HCCs were characterized by pseudoacinar architecture, small and uniform cell size with hydropic cytoplasmic changes, bile staining, and the absence of fibrosis and steatosis.
RFTA treatment. One hundred and sixty-six (80.2%) patients were treated by percutaneous RFTA; 24 (11.6%) were treated by laparoscopic (IO) RFTA; and 17 (8.2%) were treated by arterial stop-flow (TAE) RFTA. After a first treatment session, 156 (75.4%) patients achieved a complete response, whereas 51 (24.6%) had an incomplete response and received a second session at the end, of which 8 (3,9%) were considered to have treatment failure. Similar failure rates were observed for the treatment of recurrent lesions (data not shown). Major complications reported included transitory liver decompensation (1) and liver abscess (1) for percutaneous RFTA, transitory (Table 3) .
Univariate and multivariate analysis was done to assess the clinical and pathologic variables correlated to HCC recurrence (Table 4) . By univariate analysis, number of nodules, AFP levels, and tumor fibrosis were risk factors, whereas GS was protective. By multivariate analysis, only AFP levels and GS staining maintained a significant effect. β-Catenin staining did not correlate with recurrence.
At the end of follow-up, 113 (54.6%) patients were dead, corresponding to an overall mortality rate of 16.3 (14-20) per 100 patients/year (Table 3) . Sixty-seven (32.4%) patients died for advanced cancer corresponding to a tumor-specific mortality rate of 9.57 (7-12) per 100 patients/year. Of the remaining 46 patients, 45 died for unrelated causes (6 other malignancies, 7 cardiovascular disease, 3 renal failure, 1 trauma, 1 myastenia gravis) or for deterioration of their liver disease (27 patients). In one patient, the cause of death was unknown. Of these patients, 33 were free from HCC and 13 had persistent disease, 9 had limited local recurrences, and 4 had advanced diseases under control. At the end of follow-up, 94 patients were alive, 23 (24.5%) of whom had persistent disease. Both overall (12.4 versus 20.0; P = 0.006) and tumor-specific (7.4 versus 11.5; P = 0.036) mortality incidence rates were significantly reduced in GS-positive patients.
Survival analysis. Risk factors of overall and tumorspecific mortality were tested by univariate and multivariate logistic regression analysis. By univariate analysis, overall mortality correlated with age, number of recurrences, nonlocal recurrence, advanced disease, nuclear grade 3, fibrosis, and GS-negative status (Table 5) . Tumor-specific mortality correlated with local and nonlocal tumor recurrence, advanced disease, posttreatment AFP levels, and GS-negative status (Table 5 ). Cumulative overall and specific mortality rates at 3 years for GS-positive patients were 22% (95% CI, 14-33) and 17% (95% CI, 9-26), respectively, compared with 42% (95% CI, 33-52) and 25% (95% CI, 17-36) for GS-negative subjects (Fig. 1) .
The multivariate model for overall mortality included age, sex, type of RFTA treatment, local and nonlocal recurrence, advanced disease, posttreatment AFP levels, nuclear grade, fibrosis, and GS status ( Research.
on April 14, 2017. © 2010 American Association for Cancer clincancerres.aacrjournals.org Downloaded from was excluded from the model due to colinearity with GS. Tumor-specific mortality correlated with nonlocal recurrence (HR, 4.09; 95% CI, 2.03-8.17), posttreatment AFP levels (HR, 1.90; 95% CI, 1.10-3.25), and GS positivity (HR, 0.58; 95% CI, 0.34-0.97).
Discussion
The diagnosis of HCC can be reliably reached by concordant findings of two imaging techniques and/or AFP levels in nodules ≥2.0 cm (29) . Focused biopsy is indicated only to discriminate equivocal findings in smaller HCCs. Therefore, the main emphasis of pathology has been on the differential diagnosis of early neoplasia (30) rather than on markers of prognosis. Tumor grade, growth pattern, and vessel invasion correlate with survival, but these pathologic variables can be evaluated only in the minority of resected tumors (31) .
We show that the pathologic evaluation of HCC on percutaneous biopsy provides insights on the biology and the clinical course of tumors. Immunostaining for GS, a marker of wnt signaling activation, identifies a tumor subset with distinct morphology and 50% reduction of the risk of death at a median of 3 years following RFTA. The study design complies with state-of-art methodologic requirements such as use of time-to-event primary survival end points, control of counfounding by multivariate regression, and competing risk analysis (32) . Different and alternative mechanisms can activate the wnt canonical pathway including mutations of β-catenin (19, 33) , and axin (34), upregulation of frizzled-7 (35), and GSK3β inactivation (36) . β-Catenin mutations have been reported in 20% (4-41%) of HCCs, but the sensitivity and specificity of nuclear β-catenin in predicting gene mutation is limited (8, 10, (13) (14) (15) (16) (17) (18) . Previous studies indicate that HCCs with nuclear β-catenin or gene mutation display a distinct clinic-pathologic profile (10, (13) (14) (15) . However, evidence about an effect on prognosis is limited and controversial (14) (15) (16) (17) (18) .
As immunoreactivity or mutation analysis of β-catenin may not represent sufficiently accurate markers of wnt pathway activation, we used GS staining for tumor typing based on several lines of evidence. First, both in human and transgenic models of HCC, GS expression strongly correlates with levels of wnt/β-catenin signaling (11, 12, 21, 37) . Second, we observed the nuclear translocation of β-catenin only among GS-positive HCCs. Third, we sequenced β-catenin in 86 HCCs and found mutations only among GS-positive tumors (13) . Fourth, we performed array-CGH in a series of HCCs and showed segregation of genomic patterns according to GS status. 5 We considered a large number HCCs that underwent liver biopsy and were uniformly treated by RFTA, an approach that should reduce the bias of selection compared with surgical series. In fact, ∼50% of newly diagnosed HCC in our institution underwent RFTA compared with 2% of resections. Other distinctive points were the analysis of a mono-institutional series, the uniform racial and etiologic background of patients and the homogeneous criteria of enrollment, diagnosis and treatment of primary tumor, and recurrences. Biases related to the retrospective nature of the study should be limited as we included only consecutive cases representing 50% of all RFTA treatments and 91.9% of all biopsies over the period. About the classification of cases and controls, several arguments support a correct attribution of the GS status. First, we examined 85.8% of all nodules and evaluated GS staining in 92.5% of primary tumors. Second, GS staining was reproducible in all 35 tumors with multiple biopsies. Third, the comparison of GS staining in paired biopsy and resection specimens gave 97% agreement. Fourth, the prevalence of GS staining was comparable with that reported by other authors (13, 22) .
Our main conclusion is that the pathologic assessment of early HCC on percutaneous biopsy predicts survival after RFTA and can be used to stratify patients in classes of risk. By univariate analysis, the only pretreatment variables affecting survival were pathologic features such as nuclear grade, fibrosis, and GS status. All other predictive factors related to the posttreatment course, in particular the number and timing of recurrent events. By multivariate analysis, GS status was the only pretreatment variable affecting both tumor-specific and overall survival. The strength of prediction provided by this single marker is comparable with that achieved by complex gene profiling techniques (38) .
The results offer limited insights to explain the observed differences of outcome. The sequence of recurrences leading to advanced disease was similar between groups but the time-to-event was shorter in GS-positive patients. This could not be explained by a different efficacy of RFTA because incomplete treatment and treatment failure rates were similar among patients. The limited assessment allowed by the needle biopsy precluded the study of relevant pathologic variables such as underlying liver disease, proliferative indices, or patterns of liver and portal invasion that might help in the interpretation of clinical courses. Notably, wnt-activated HCCs induced in experimental animals are better differentiated, less aggressive, and display activation of specific metabolic pathways (11, 12, 39) .
In addition to GS status, other pathologic variables might potentially affect survival, in particular steatosis and fibrosis. Interestingly, both were inversely correlated with GS staining, and fibrosis was associated with an unfavorable outcome. As new drugs that target the signaling pathways of wnt-activated HCCs become available (40) , the identification of this tumor subset might have wider clinical implications.
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